SK15122003A3 - Imunogénne konjugáty nízkomolekulárnej kyseliny hyalurónovej s polypeptidovými toxínmi - Google Patents

Imunogénne konjugáty nízkomolekulárnej kyseliny hyalurónovej s polypeptidovými toxínmi Download PDF

Info

Publication number
SK15122003A3
SK15122003A3 SK1512-2003A SK15122003A SK15122003A3 SK 15122003 A3 SK15122003 A3 SK 15122003A3 SK 15122003 A SK15122003 A SK 15122003A SK 15122003 A3 SK15122003 A3 SK 15122003A3
Authority
SK
Slovakia
Prior art keywords
hyaluronic acid
molecular weight
low molecular
group
conjugate
Prior art date
Application number
SK1512-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Francis Michon
Samuel Moore
Maryline Laude-Sharp
Milan Blake
Original Assignee
Baxter International Inc.
Baxter Healthcare S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc., Baxter Healthcare S. A. filed Critical Baxter International Inc.
Publication of SK15122003A3 publication Critical patent/SK15122003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SK1512-2003A 2001-05-11 2002-05-10 Imunogénne konjugáty nízkomolekulárnej kyseliny hyalurónovej s polypeptidovými toxínmi SK15122003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,367 US20020192205A1 (en) 2001-05-11 2001-05-11 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
PCT/EP2002/005310 WO2002092131A2 (en) 2001-05-11 2002-05-10 Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins

Publications (1)

Publication Number Publication Date
SK15122003A3 true SK15122003A3 (sk) 2004-10-05

Family

ID=25315838

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1512-2003A SK15122003A3 (sk) 2001-05-11 2002-05-10 Imunogénne konjugáty nízkomolekulárnej kyseliny hyalurónovej s polypeptidovými toxínmi

Country Status (15)

Country Link
US (1) US20020192205A1 (pl)
EP (1) EP1385554A2 (pl)
JP (1) JP2005508854A (pl)
KR (1) KR20030096369A (pl)
CN (1) CN1525869A (pl)
AR (1) AR034331A1 (pl)
BR (1) BR0209562A (pl)
CA (1) CA2446555A1 (pl)
CO (1) CO5550467A2 (pl)
EC (1) ECSP034888A (pl)
HU (1) HUP0400840A3 (pl)
MX (1) MXPA03010283A (pl)
PL (1) PL366692A1 (pl)
SK (1) SK15122003A3 (pl)
WO (1) WO2002092131A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CA2773755C (en) * 2008-09-09 2017-04-25 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CN102264444B (zh) * 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
CN102010469B (zh) * 2010-10-22 2013-02-27 上海贝西生物科技有限公司 一种抗透明质酸单克隆抗体及其用途
CN104302670A (zh) * 2012-02-07 2015-01-21 Phi生物医药股份有限公司 制造用于经皮给药的透明质酸-蛋白结合体的方法以及由该方法制造的用于经皮给药的透明质酸-蛋白结合体
CN104237500B (zh) * 2014-09-30 2016-09-28 博奥赛斯（天津）生物科技有限公司 一种透明质酸固相包被方法
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
IT201900022626A1 (it) * 2019-12-02 2021-06-02 Ub Care S R L Metodo per la determinazione del contenuto di sodio ialuronato in un idrogel
CN115590774B (zh) * 2022-10-20 2024-05-03 珠海原妙医学科技股份有限公司 透明质酸脂质体组装体及其制备方法和应用
CN119158011A (zh) * 2024-05-30 2024-12-20 江苏坤力生物制药有限责任公司 一种增强重组蛋白抗原免疫原性的方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
JPH0912600A (ja) * 1995-06-22 1997-01-14 Shiseido Co Ltd ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法
CA2297072A1 (en) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
CA2332455C (en) * 1998-06-01 2012-08-14 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Also Published As

Publication number Publication date
BR0209562A (pt) 2004-03-30
WO2002092131A2 (en) 2002-11-21
US20020192205A1 (en) 2002-12-19
JP2005508854A (ja) 2005-04-07
HUP0400840A2 (hu) 2004-07-28
AR034331A1 (es) 2004-02-18
KR20030096369A (ko) 2003-12-24
CO5550467A2 (es) 2005-08-31
CA2446555A1 (en) 2002-11-21
HUP0400840A3 (en) 2004-10-28
CN1525869A (zh) 2004-09-01
WO2002092131A3 (en) 2003-03-20
EP1385554A2 (en) 2004-02-04
PL366692A1 (pl) 2005-02-07
ECSP034888A (es) 2004-05-28
MXPA03010283A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
JP4097691B2 (ja) Ｃ群髄膜炎菌に対するワクチン
US6602508B2 (en) Method of immunization using a Group B Streptococcus type II and type III polysaccharide conjugate vaccine
AU2005316864B2 (en) Glycoconjugate vaccines containing peptidoglycan
Liao et al. Synthesis and immunological study of α-2, 9-oligosialic acid conjugates as anti-group C meningitis vaccines
JP2008201793A (ja) Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
JP2004505885A (ja) Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
IL147121A (en) Meningococcal polysaccharide conjugate vaccines
US20020192205A1 (en) Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
US7211445B2 (en) Conjugation of biomolecules using diels-alder cycloaddition
WO2006096970A1 (en) Synthetic anti-candida albicans oligosaccharide based vaccines
US20100209448A1 (en) Synthetic anti-candida albicans oligosaccharide based vaccines
KR100433986B1 (ko) 식물또는과실의폴리사카라이드로부터합성된장티푸스백신및그제법
JPH04507244A (ja) リピドａ類似体／免疫原性担体コンジュゲートおよびそのワクチンとしての使用
US7527949B2 (en) Polysaccharides of Helicobacter pylori
EP1000076A1 (en) HEXADECASACCHARIDE-PROTEIN CONJUGATE VACCINE FOR $i(SHIGELLA DYSENTERIAE) TYPE 1
AU2002342321A1 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
CN114073761A (zh) 一种寡糖缀合物及其作为预防v型b族链球菌感染糖疫苗的应用
MXPA00008255A (en) Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines